(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...